Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients
Open accessAbstract
CD4+ T cells have been shown to be crucial for the induction and maintenance of cytotoxic T cell responses and to be also capable of mediating direct tumor rejection. Therefore, the anticancer therapeutic efficacy of peptide‐based vaccines may be improved by addition of HLA class II epitopes to stimulate T helper cells. Survivin is an apoptosis inhibiting protein frequently overexpressed in tumors. Here we describe the first immunological evaluation of a survivin‐derived CD4+ T cell epitope in a multipeptide immunotherapy trial for prostate carcinoma patients. The survivin peptide is promiscuously presented by several human HLA‐DRB1 molecules and, most importantly, is naturally processed by dendritic cells. In vaccinated patients, it was able to induce frequent, robust and multifunctional CD4+ T cell responses, as monitored by IFN‐γ ELISPOT and intracellular cytokine staining. Thus, this HLA‐DR restricted epitope is broadly immunogenic and should be valuable for stimulating T helper cells in patients suffering from a wide range of tumors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In an HLA-A*02:01+ patient population, epitopes of the expressed TAAs will also be presented on the tumours of most patients to the immune system, because CVGBM encodes HLA-A*02:01-restricted epitopes for three of the TAAs and a pan-DR-restricted epitope for the fourth TAA (Survivin), which is presented by many HLA class II molecules.
“Importantly, in an HLA-A*02:01+ patient population, epitopes of the expressed TAAs will also be presented on the tumours of most patients to the immune system, as CVGBM encodes HLA-A*02:01-restricted epitopes for three of the TAAs (BCAN, NLGN4X, PTPRZ1) and a pan-DR-restricted epitope for the fourth TAA (Survivin), which is presented by many HLA class II molecules [29].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [29]
Cites
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,167 · see citing works
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615 · see citing works
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,868 · see citing works
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · see citing works
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N. H., Wallen, H. D., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R. M., Jungbluth, A. A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 904 · see citing works
Sun, J. C.-Y., Williams, M. A., & Bevan, M. J. (2004) · Nature Immunology · doi:10.1038/ni1105 · Cited by 644 · see citing works
OSSENDORP, F. A., Mengedé, E., Camps, M. G. M., Filius, R., & Melief, C. J. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.693 · Cited by 609 · see citing works
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Wang, H. Y., Lee, D. A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E. M., & Wang, R. (2004) · Immunity · doi:10.1016/s1074-7613(03)00359-5 · Cited by 515 · see citing works
Qin, Z., & Blankenstein, T. J. F. (2000) · Immunity · doi:10.1016/s1074-7613(00)80218-6 · Cited by 511 · see citing works
Schuler‐Thurner, B., Schultz, E. S., Berger, T. G., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012100 · Cited by 476 · see citing works
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465 · see citing works
CD4 cells can be more efficient at tumor rejection than CD8 cells
Pérez‐Díez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O. J., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 436 · see citing works
Islam, A., Kageyama, H., Takada, N., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203358 · Cited by 387 · see citing works
CD4 + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Mumberg, D., Monach, P. A., Wanderling, S. S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8633 · Cited by 385 · see citing works
Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma
Grossman, D., McNiff, J. M., Li, F., & Altieri, D. C. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00776.x · Cited by 364 · see citing works
Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
Adida, C., Haïoun, C., Gaulard, P., et al. (2000) · PubMed · doi:10.1182/blood.v96.5.1921 · Cited by 360 · see citing works
Casazza, J. P., Betts, M. R., Price, D. A., Precopio, M., Ruff, L. E., Brenchley, J. M., Hill, B. J., Roederer, M., Douek, D. C., & Koup, R. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052246 · Cited by 338 · see citing works
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302 · see citing works
Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer
Swana, H. S., Grossman, D., Anthony, J. N., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410614 · Cited by 302 · see citing works
A systematic review of humoral immune responses against tumor antigens
Reuschenbach, M., Doeberitz, M. V. K., & Wentzensen, N. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0733-4 · Cited by 281 · see citing works
Schmidt, S. M., Schag, K., Müller, M., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2554 · Cited by 277 · see citing works
Odunsi, K. O., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P. Y., Andrews, C., Hoffman, E. W., Pan, L. S., Ritter, G., Villella, J., Thomas, B. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703342104 · Cited by 269 · see citing works
Schmitz, M., Diestelkoetter, P., Weigle, B., et al. (2000) · PubMed · Cited by 219 · see citing works
van der Burg, S. H., Piersma, S. J., de Jong, A., van der Hulst, J. M., Kwappenberg, K. M. C., van den Hende, M., Welters, M. J. P., van Rood, J. J., Fleuren, G. J., Melief, C. J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704672104 · Cited by 218 · see citing works
Bonertz, A., Weitz, J., Pietsch, D. K., Rahbari, N. N., Schlude, C., Ge, Y., Juenger, S., Vlodavsky, I., Khazaie, K., Jaeger, D., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39608 · Cited by 200 · see citing works
Scheel, B., Teufel, R., Probst, J., Carralot, J., Geginat, J., Radsak, M. P., Jarrossay, D., Wagner, H., Jung, G., Rammensee, H., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200425656 · Cited by 198 · see citing works
Self-citationExpression of survivin in normal, hyperplastic, and neoplastic colonic mucosa
Gianani, R., Jarboe, E. A., Orlicky, D. J., et al. (2001) · Human Pathology · doi:10.1053/hupa.2001.21897 · Cited by 182 · see citing works
Tsuruma, T., Hata, F., Torigoe, T., Furuhata, T., Idenoue, S., Kurotaki, T., Yamamoto, M., Yagihashi, A., Ohmura, T., Yamaguchi, K., et al. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-19 · Cited by 181 · see citing works
Wobser, M., Keikavoussi, P., Kunzmann, V., Weininger, M. J., Andersen, M. H., & Becker, J. C. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0102-x · Cited by 161 · see citing works
Xiang, R., Mizutani, N., Luo, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.553.65.2 · Cited by 159 · see citing works
Britten, C. M., Gouttefangeas, C., Welters, M. J. P., Pawelec, G., Koch, S. D., Ottensmeier, C. H. H., Mander, A., Walter, S., Paschen, A., Müller‐Berghaus, J., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0378-0 · Cited by 143 · see citing works
Self-citationBuckner, J. C., Schomberg, P. J., McGinnis, W. L., Cascino, T. L., Scheithauer, B. W., O'Fallon, J. R., Morton, R. F., Kuross, S. A., Mailliard, J. A., Hatfield, A. K., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2 · Cited by 138 · see citing works
Fuessel, S., Meye, A., Schmitz, M., Zastrow, S., Linné, C., Richter, K., Löbel, B., Hakenberg, O. W., Hoelig, K., Rieber, E. P., et al. (2006) · The Prostate · doi:10.1002/pros.20404 · Cited by 125 · see citing works
Idenoue, S., Hirohashi, Y., Torigoe, T., Sato, Y., Tamura, Y., Hariu, H., Yamamoto, M., Kurotaki, T., Tsuruma, T., Asanuma, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0817 · Cited by 122 · see citing works
Slingluff, C. L., Petroni, G. R., Olson, W. C., Czarkowski, A. R., Grosh, W. W., Smolkin, M. E., Chianese‐Bullock, K. A., Neese, P. Y., Deacon, D. H., Nail, C. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3161 · Cited by 118 · see citing works
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin
Otto, K., Andersen, M. H., Eggert, A. O., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.08.007 · Cited by 112 · see citing works
Feyerabend, S., Stevanović, S., Gouttefangeas, C., et al. (2009) · The Prostate · doi:10.1002/pros.20941 · Cited by 108 · see citing works
Self-citationZeis, M., Siegel, S., Wagner, A., Schmitz, M., Marget, M., Kühl-Burmeister, R., Adamzik, I.-D., Kabelitz, D., Dreger, P., Schmitz, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5391 · Cited by 105 · see citing works
Mine, T., Sato, Y., Noguchi, M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1117-3 · Cited by 105 · see citing works
Casati, C., Dalerba, P. D., Rivoltini, L., Gallino, G., Deho, P., Rini, F., Belli, F., Mezzanzanica, D., Costa, A., Andreola, S. A., et al. (2003) · PubMed · Cited by 96 · see citing works
Attig, S., Hennenlotter, J., Pawelec, G., Klein, G., Koch, S. D., Pircher, H., Feyerabend, S., Wernet, D., Stenzl, A., Rammensee, H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0852 · Cited by 91 · see citing works
Self-citationFrançois, V., Ottaviani, S., Renkvist, N., Stockis, J., Schuler, G., Thielemans, K., Colau, D., Marchand, M., Boon, T., Lucas, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3726 · Cited by 90 · see citing works
Kornacker, M., Verneris, M. R., Kornacker, B., et al. (2001) · Immunology Letters · doi:10.1016/s0165-2478(01)00186-9 · Cited by 60 · see citing works
HLA‐B35‐restricted immune responses against survivin in cancer patients
Hadrup, S. R., Becker, J. C., Svane, I. M., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.11634 · Cited by 53 · see citing works
Lladser, Á., Ljungberg, K., Tufvesson, H., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0725-4 · Cited by 52 · see citing works
Wang, X., Kerzerho, J., Adotévi, O., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.431 · Cited by 44 · see citing works
Turvy, D. N., & Blum, J. S. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00206-8 · Cited by 27 · see citing works
Shebzukhov, Y. V., Lavrik, I. N., Karbach, J., Khlgatian, S. V., Koroleva, E. P., Belousov, P. V., Кашкин, К. Н., Knuth, A. K., Jäger, E., Chi, N., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0423-z · Cited by 27 · see citing works
Self-citationHadrup, S. R., Gehl, J., Sørensen, R. B., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.5.2652 · Cited by 24 · see citing works
Piesche, M., Hildebrandt, Y., Zettl, F., et al. (2007) · Human Immunology · doi:10.1016/j.humimm.2007.03.007 · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938 · see citing works
Self-citationHinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27303-7 · Cited by 175 · see citing works
Migliorini, D., Dutoit, V., Allard, M., Grandjean Hallez, N., Marinari, E., Widmer, V., Philippin, G., Corlazzoli, F., Gustave, R., Kreutzfeldt, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz040 · Cited by 147 · see citing works
Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma
Lutz, J., Feist, R. K., Sonntag, T., Peguero-Sánchez, E., Wolter, K., Bick, R., Bauer, J., Walz, J. S., & Heidenreich, R. (2025) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-025-04178-x · Cited by 9 · see citing works
- Authors
- Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., Pascolo, S., Stenzl, A., Gouttefangeas, C., & Rammensee, H.
- Affiliations
- University of Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Corresponding author
- Gouttefangeas, Cécile
- ORCID
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-09-14
- Volume
- 131
- Issue
- 1
- Pages
- 140-149
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2094294085
- Cited by
- 70
- References
- 50
- Citations by year
- 2025: 4 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 8 · 2017: 4 · 2016: 7 · 2015: 6 · 2014: 9 · 2013: 7 · 2012: 1
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- survivin, CD4+ T cell epitopes, HLA-DRB1, HLA class II epitopes, peptide-based cancer vaccines, prostate cancer, interferon-gamma, cancer immunotherapy, apoptosis inhibitor
- MeSH terms
- Survivin, Aged, Antigens, Neoplasm, Dendritic Cells, T-Lymphocytes, Helper-Inducer, Humans, Interferon-gamma, Lymphocyte Activation, Male, Middle Aged, Peptide Fragments, Prostatic Neoplasms, T-Lymphocytes, Cytotoxic, Cytokines, Epitopes, T-Lymphocyte, Cancer Vaccines, Inhibitor of Apoptosis Proteins, HLA-DRB1 Chains
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
